A widely studied example is pancreatic cancer, where mutant KRAS signaling leads to activation of MEK (mitogen-activated protein kinase/extracellular signal–regulated kinase [ERK])–ERK and downstream signaling, which promotes oncogenic mechanisms, including cell proliferation. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.